Abstract
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine that is tightly regulated and expressed at low levels in healthy individuals. Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease (obesity, myocardial infarction and type II diabetes). Cytokines including IL-6 and tumour necrosis factor alpha as well as acute phase proteins such as C-reactive protein (CRP) and fibrinogen are key biochemical risk factors for the development of these disease conditions. IL-6 is the key cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the signalling receptor gp130. Assembly of the (hexameric) signalling complex of IL-6, IL-6R and gp130 occurs in a sequential manner and therefore this signalling complex lends itself to several potential sites for drug targeting. This review discusses some of the mechanisms of IL-6 signalling on various aspects of cardiovascular biology as well as some recent developments in drug targeting of this complex.
Keywords: Interleukin-6, inflammation, cardiovascular disease, endothelium, C-reactive protein, insulin resistance
Current Pharmaceutical Design
Title: Cardiovascular Biology of Interleukin-6
Volume: 15 Issue: 15
Author(s): Mahinda Y. Abeywardena, Wayne R. Leifert, Kirsty E. Warnes, Jose N. Varghese and Richard J. Head
Affiliation:
Keywords: Interleukin-6, inflammation, cardiovascular disease, endothelium, C-reactive protein, insulin resistance
Abstract: Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine that is tightly regulated and expressed at low levels in healthy individuals. Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease (obesity, myocardial infarction and type II diabetes). Cytokines including IL-6 and tumour necrosis factor alpha as well as acute phase proteins such as C-reactive protein (CRP) and fibrinogen are key biochemical risk factors for the development of these disease conditions. IL-6 is the key cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the signalling receptor gp130. Assembly of the (hexameric) signalling complex of IL-6, IL-6R and gp130 occurs in a sequential manner and therefore this signalling complex lends itself to several potential sites for drug targeting. This review discusses some of the mechanisms of IL-6 signalling on various aspects of cardiovascular biology as well as some recent developments in drug targeting of this complex.
Export Options
About this article
Cite this article as:
Abeywardena Y. Mahinda, Leifert R. Wayne, Warnes E. Kirsty, Varghese N. Jose and Head J. Richard, Cardiovascular Biology of Interleukin-6, Current Pharmaceutical Design 2009; 15 (15) . https://dx.doi.org/10.2174/138161209788186290
DOI https://dx.doi.org/10.2174/138161209788186290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aging and Oral Health: Effects in Hard and Soft Tissues
Current Pharmaceutical Design Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Is Mental Practice an Effective Adjunct Therapeutic Strategy for Upper Limb Motor Restoration After Stroke? A Systematic Review and Meta- Analysis
CNS & Neurological Disorders - Drug Targets Serum Albumin Concentration and Cognitive Impairment
Current Alzheimer Research C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Role of Antiplatelet Therapy in Primary Prevention. A Review
Current Pharmaceutical Design Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery